Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 26, 2026

NatWest cuts mortgage costs ahead of spring statement

View original at uk.finance.yahoo.com
NatWest cuts mortgage costs ahead of spring statement NatWest has cut borrowing costs this week as most lenders adopted a wait-and-see approach ahead of the spring statement that is due on 3 March…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The change was part of a reprice following the changes to swaps after the Bank of England held interest rates

    80% confidence

  • Consumer prices rose 3% in the year to January, down from 3.4% in December

    80% confidence

  • Financial markets are pricing in a 0.25 percentage point reduction in the Bank of England's base rate to 3.5% at its meeting on 19 March

    80% confidence

  • Average five-year fixed deal came in at 4.99%, up from the previous 4.94%

    80% confidence

  • It is widely expected that no major housing reforms will be announced in Rachel Reeves's statement

    80% confidence

  • Average rate for two-year fixed mortgage came in at 4.75% this week, higher than last week's 4.53%

    80% confidence

  • It marks the lowest reading for the Consumer Price Index since March last year

    80% confidence

Data points we hold from this source

Barclays · five year fixed mortgage rate4.00 percent
Barclays · two year fixed mortgage rate3.70 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
NatWest cuts mortgage costs ahead of spring statement — Source | Via News | ViaNews EU